Methodology: Regenerative Medicine Deals

The methodology behind Datamonitor Healthcare's new Regenerative Medicine Landscape report.

For deal-making trends, deals are grouped into three main categories: gene therapy, cell therapy and tissue regeneration. There may be overlap among the categories in terms of deals included in each if they cross over more than one of those categories. The sources for these data are Informa's Medtrack and Strategic Transactions. The regenerative medicine industries covered from Medtrack include biomaterials and tissue regeneration (which were included in the tissue regeneration category), in vivo and ex vivo gene therapy (in the gene therapy category) and stem cell therapy (in the cell therapy category). Within Medtrack's partnership classification are funding/grant announcements, as well as some deals focused on the veterinary market. The regenerative medicine industries covered from Strategic Transactions include "gene therapy, cell therapy" and biomaterials. The deals labeled "gene therapy, cell therapy" were individually reviewed and placed into one or more of the three main categories. The biomaterials deals were included in the tissue regeneration category. Keyword searching of deal summaries was also used in Strategic Transactions to identify regenerative medicine deals. Gene editing deals are included in the gene therapy category.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from In Vivo

The 360 Degrees Of European Biotech Financing In 2025

 
• By 

Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.

Rising Leaders 2025: Pedro Valencia’s ADC Vision At AbbVie

 
• By 

From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.

Leaders At The Frontier: Conversations From SynBioBeta 2025

 
• By 

Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.